Asset Details
Do you wish to reserve the book?
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Do you wish to request the book?
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
2017
Overview
With a median follow-up of 13 years, a randomized comparison of radiotherapy with or without antiandrogen therapy in patients with a rising PSA level after prostatectomy showed that 2 years of antiandrogen therapy resulted in a significantly higher overall survival rate.
Patients with localized prostatic cancer are often treated with radical prostatectomy. More than 30% of such patients will subsequently have recurrence. This recurrence manifests first as a rising serum level of prostate-specific antigen (PSA),
1
–
3
termed biochemical recurrence. Large, retrospective studies suggest that salvage radiation therapy after biochemical recurrence may be associated with long-term freedom from cancer recurrence.
4
,
5
However, 50% of the patients who are treated with salvage radiation therapy will have further disease progression, particularly when there are aggressive disease features.
4
–
7
The combination of radiation therapy and either androgen-deprivation therapy or antiandrogen therapy prolongs survival among some . . .
Publisher
Massachusetts Medical Society
Subject
/ Androgen Antagonists - adverse effects
/ Androgen Antagonists - therapeutic use
/ Death
/ Gynecomastia - chemically induced
/ Humans
/ Male
/ Neoplasm Recurrence, Local - drug therapy
/ Neoplasm Recurrence, Local - mortality
/ Neoplasm Recurrence, Local - radiotherapy
/ Oncology
/ Prostatic Neoplasms - drug therapy
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - radiotherapy
/ Prostatic Neoplasms - surgery
/ Radiotherapy - adverse effects
/ Survival
/ Tablets
/ Tosyl Compounds - adverse effects
